Therapy Areas: Inflammatory Diseases
Chinese regulator accepts Lynk Pharmaceuticals' New Drug Application for zemprocitinib in RA treatment
6 November 2026 - Lynk Pharmaceuticals Co Ltd, a clinical-stage innovative drug company focused on autoimmune and inflammatory diseases, announced on Thursday that the New Drug Application (NDA) for i...
ABIONYX Pharma partners with Lille University Hospital to explore CER-001 for severe burn patients
4 November 2026 - ABIONYX Pharma (Euronext Paris:ABNX), a biopharma company focused on breakthrough biotherapies to address life-threatening conditions with no effective treatments, announced on Wedne...
Merck launches Phase 3 trial of Ohtuvayre for COPD exacerbation prevention
3 November 2026 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Tuesday that it has initiated ENHANCE-3, a Phase 3 clinical trial evalua...
Bambusa Therapeutics prices upsized initial public offering
30 October 2026 - Bambusa Therapeutics Inc (Nasdaq:BBTX), a clinical-stage biopharmaceutical company developing next-generation, long-acting precision bispecific antibodies for immunology and inflamma...
Evogene targets acute graft-versus-host disease for AI-driven drug discovery programme
28 October 2026 - Computational chemistry company Evogene Ltd (NASDAQ: EVGN) (TASE: EVGN) announced on Wednesday that it has selected acute graft-versus-host disease (aGVHD) as the target indication f...
Lynk Pharmaceuticals reports positive Phase III trial results for zemprocitinib in rheumatoid arthritis
28 October 2026 - Lynk Pharmaceuticals Co Ltd, a Chinese drug development company focused on immune and inflammatory diseases, on Tuesday announced positive long-term results from its pivotal Phase II...